MoonLake Immunotherapeutics (MEX:MLTXN) Total Equity: MXN4,580.74 Mil (As of Mar. 2026)


MEX:MLTXN MoonLake Immunotherapeutics MEX:MLTXN
30 GF Score
Price MXN305.30
! 3 Warning Signs
View Full Analysis

What is MoonLake Immunotherapeutics Total Equity?

MoonLake Immunotherapeutics MEX:MLTXN 30 Total Equity is MXN4,580.74 Mil as of Mar. 2026. GuruFocus rates MEX:MLTXN with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

MoonLake Immunotherapeutics's total equity for the quarter that ended in Mar. 2026 was MXN4,580.74 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

MoonLake Immunotherapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for MoonLake Immunotherapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MoonLake Immunotherapeutics Total Equity Chart

MoonLake Immunotherapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
-238.89 1,340.68 8,716.12 9,455.79 5,482.39

MoonLake Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,440.67 6,739.80 5,341.67 5,482.39 4,580.74
MEX:MLTXN
30GF Score
MoonLake Immunotherapeutics MEX:MLTXN
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MoonLake Immunotherapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

MoonLake Immunotherapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=7642.213-2159.82
=5,482.39

MoonLake Immunotherapeutics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=7219.824-2639.086
=4,580.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of MXN4,580.74 Mil mean?
MoonLake Immunotherapeutics (MEX:MLTXN) has a Total Equity of MXN4,580.74 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for MoonLake Immunotherapeutics and its competitors.
Is MoonLake Immunotherapeutics' Total Equity too high?
MoonLake Immunotherapeutics' current Total Equity is MXN4,580.74 Mil. Overall, MoonLake Immunotherapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' Total Equity compare to AVBP and BCAX?
MoonLake Immunotherapeutics' Total Equity of MXN4,580.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for MoonLake Immunotherapeutics and its competitors. MoonLake Immunotherapeutics's current Total Equity is MXN4,580.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MEX:MLTXN) has a current Total Equity of MXN4,580.74 Mil. The current Total Equity is MXN4,580.74 Mil. MoonLake Immunotherapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MEX:MLTXN), the current Total Equity is MXN4,580.74 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MoonLake Immunotherapeutics Business Description

Other Exchanges MLTX:USA
Address Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
30GF Score

Get the complete analysis for MEX:MLTXN

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN305.30
Price